QL1706

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, The Second Hospital Affiliated to Air Force Medical University, Qilu Pharmaceutical,

Abstract

Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study.

Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Yunnan Cancer Hospital, Kunming, Yunnan, China, Anhui Chest Hospital,

Abstract

A phase III, multicenter, double-blinded, randomized, active-controlled study on the efficacy and safety of QL1706 with chemotherapy (CT) as first-line therapy for PD-L1–negative advanced or metastatic non–small-cell lung cancer (NSCLC).

Org: Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center & State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China, Medicine Department, Qilu Pharmaceutical Co., Ltd., Jinan, China,

Product

QL1706 + paclitaxel + cisplatin + radiotherapy

Abstract

An open-label, multicenter, adaptive, phase Ib/II study of QL1706 or QL1604 plus bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.

Org: Department of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, China, Department of Gastroenterology Second Ward, Harbin Medical University Cancer Hospital, Harbin, China, Department of Intervention,Hunan Cancer Hosptial, Changsha, China, Liver Tumor Center, Nanfang Hospital Southern Medical University, Guangzhou, China, Phase I Clinical Research Room,Nanfang Hospital Southern Medical University, Guangzhou, China,